Alzheimer's Boom or Bust
EconRx
Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story. email: Twitter/Instagram: @EconRx LinkedIn: Website:
info_outline
$35 Insulin Cap
EconRx
Capping patient out-of-pocket costs for insulin has been a popular move for legislators, most recently by the US House. On this episode we weigh the Pros, Cons, and viral reactions to this move including lowering vs. shifting costs, ADA guidelines, and political theater. email: Twitter/Instagram: @EconRx LinkedIn: Website:
info_outline
Testing Woes & Ivermectin
EconRx
After explaining a HORRENDOUS mistake made recently by the NABP and the oversight of NAPLEX testing that affected one of our own, we decided it's high time we dove into the controversy around the use of ivermectin against COVID-19. Social media and mainstream news can be confusing, so we tried to summarize while sticking to what we know.
info_outline
Blueberry Pharmacy
EconRx
On this episode we were blessed to have on Kyle McCormick, owner/operator of Blueberry Pharmacy, to explain his unique business model. Blueberry operates on a cost-plus model and DOES NOT ACCEPT INSURANCE. Crazy? Maybe not.
info_outline![[NEWSFLASH] Amazon: Usual & Customary show art](https://assets.libsyn.com/item/19713728?height=50&width=50)
[NEWSFLASH] Amazon: Usual & Customary
EconRx
The Twittersphere recently noticed that quoted savings on Amazon Pharmacy are a little bit unrealistic. On this episode we break down how a pharmacy's "Usual & Customary" price SHOULD be calculated, what it is used for, and what Amazon's crazy numbers say about their pharmacy business model.
info_outline
US Drug Supply Chain
EconRx
The COVID-19 pandemic highlighted many weaknesses in the US Drug Supply Chain's dependence on foreign production (similar to toilet paper, masks, etc.). The Biden White House recently announced plans to address supply chain weaknesses to prevent future shortages due to overseas dependence.
info_outline
DIRty Money
EconRx
After a brief hiatus we are back in the studio! Everyone has important life updates to share, Aaron has some interesting learning points about Medicaid rebates, Ryan explains DIR fees, and we check back in with GoodRx's recent stock price woes.
info_outline
Mix and Match
EconRx
Since we have had guests on for the last few episodes, we wanted to take some time to cover some recent topics that have come up in the first quarter of 2021. Chosen topics:
info_outline
Kit Check
EconRx
We are beyond excited to welcome AJ Rivosecchi, PharmD onto the podcast to talk about Kit Check. A company that started as a tool for managing hospital medication inventory is growing to address drug diversion and spend optimization. Along the way they may even change industry standards for the pharmaceutical industry.
info_outline
Roche Pharmacy
EconRx
Ever been to an independent pharmacy? One with a soda fountain and ice cream bar? The level of service provided is a far cry more personal than the usual retail-pharmacy experience. Don't believe us? Hear it here straight from the Roche's mouth. Bad joke, sorry. But seriously, give @b_roche a listen and get yourself some Red Oil.
info_outlineAducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.
email: [email protected]
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/